Published in Clinical Oncology Week, April 14th, 2003
"Twenty-two adults over 70 years of age with AML were treated with an oral schedule of idarubicin (30 mg/m2/d) and etoposide (45 mg/m2/d) for 3 consecutive days," stated A. Oriol and coauthors, University of Barcelona.
"Seven (32%) achieved complete remission, seven (32%) showed absolute resistance, and eight (36%) died. The survival probability 1 year after diagnosis was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.